Vertex Pharmaceuticals Incorporated has received $0.02 as the consensus Earnings Estimate for the Quarter ending on Mar 2017 ,According to the estimate provided by 8 Financial Advisor in the Stock Trading Firms. Among 8 Analysts, Bottom line EPS Estimate for the current quarter is $-0.03 while the top line estimate is $0.1 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 118.27%.
Vertex Pharmaceuticals Incorporated reported better than expected with a surprise EPS of 1400% or $0.14 during its most recent quarterly earnings. The Actual EPS was $0.13 compared to the Estimated EPS of $-0.01. Boston based Vertex Pharmaceuticals Incorporated Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Apr 26, 2017.
In the last quarter, Vertex Pharmaceuticals Incorporated reported Annual Earnings of $0.13. Based on the filings, last years Annual Earnings was, $-0.11. In the last Quarter, VRTX reported a surprise Earnings per Share of 1400% . The consensus estimate for current quarter is $0.02 and for the current fiscal year, the estimate is $0.48. For the Next fiscal year, the estimate is $1.87 based on the consensus.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) : On Tuesday heightened volatility was witnessed in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) which led to swings in the share price. The stock opened for trading at $83.77 and hit $85.95 on the upside , eventually ending the session at $85.87, with a gain of 1.77% or 1.49 points. The heightened volatility saw the trading volume jump to 2,418,422 shares. The 52-week high of the share price is $103.73 and the company has a market cap of $21,299 million. The 52-week low of the share price is at $71.46 .
Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)